Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Major Depressive Disorder
Interventions: Ketamine, Psychotherapy; Drug · Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Amyotrophic Lateral Sclerosis
Interventions: prosetin, placebo; Drug
Lead sponsor: ProJenX; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • San Antonio, Texas

Conditions: Selected Types of Solid Tumor
Interventions: EVM14, Pembrolizumab; Biological · Combination Product
Lead sponsor: Everest Medicines (Beijing) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: New York, New York • Houston, Texas • Fairfax, Virginia

Conditions: Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
Interventions: Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging; Procedure · Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Endocare SlimLine Cryoprobe, Lumpectomy; Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hepatic Impairment
Interventions: MEK162; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: College Student Drinking
Interventions: e-checkup to go, Delayed feedback booster; Behavioral
Lead sponsor: Abby Braitman; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Diabetes Mellitus Type 2
Interventions: EGT0001442, Placebo capsules to match EGT0001442; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Birmingham, Alabama • National City, California • Denver, Colorado + 4 more

Conditions: Hypertension, Diabete Type 2
Interventions: Treatment as Usual Plus Occupational Therapy, Treatment as Usual; Behavioral
Lead sponsor: University of Indianapolis; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: This Study Has Been Designed to Compile Information on the Efficacy of the Partial Breast Intracavitary Brachytherapy in the Post Market Setting.
Interventions: Registry; Other
Lead sponsor: St. Vincent's Medical Center; Other
Eligibility: 45 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Bridgeport, Connecticut

Conditions: Fibromyalgia
Interventions: Active tDCS, Active Exercise, Sham tDCS, Sham Exercise; Device · Procedure
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Anesthesia, Opioid Use
Interventions: Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol; Behavioral · Other · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears; Drug
Lead sponsor: Senju USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Crohn's Disease
Interventions: Placebo matching with BMS-945429, BMS-945429; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: La Jolla, California • San Diego, California • Lone Tree, Colorado + 5 more

Conditions: Thrombosis
Interventions: Kcentra, Apixaban, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Degenerative Lumbar Spinal Stenosis
Interventions: Single-Level Posterior Decompression, DIAM Spinal Stabilization, Fusion; Procedure · Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 35 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 9
States / cities: Fremont, California • Jacksonville, Florida • Melbourne, Florida + 6 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Covid19
Interventions: VIR-7831 (sotrovimab), Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more

Conditions: Asthma
Interventions: FF/GSK573719, FF, FF/VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more

Conditions: Pneumococcal Infection
Interventions: V116, Placebo, PCV15, PPSV23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 518 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 58
States / cities: Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more

Conditions: Orthotopic Liver Transplant
Interventions: Everolimus, Standard Tacrolimus; Drug
Lead sponsor: Tomoaki Kato; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Cryoablation vs Lumpectomy in T1 Breast Cancers

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function

Personalized Feedback After Alcohol Health Education for Members of Greek Life (GREEK Study)

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Effect of Occupational Therapy in Promoting Medication Adherence

A Single Site Prospective, Non-randomized Study of Partial Breast Intracavitary Brachytherapy Devices to Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities.

Optimized tDCS for Fibromyalgia: Targeting the Endogenous Pain Control System

PROUD Study - Preventing Opioid Use Disorders

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Efficacy and Safety Study of QVA149 in COPD Patients

Everolimus Post Orthotopic Liver Transplant